Vivo Bio Tech disclosed that its promoter group entity, P.K.L Solution Private Limited, transferred 6,00,000 equity shares off-market on August 21, 2026. The transaction reduced the entity’s stake in the company from 2.70% to nil.

The disclosure was filed under Regulation 29(2) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. Jaivardhan Prasadam, Director of P.K.L Solution Private Limited (DIN: 00097958), signed the intimation submitted to BSE Limited.

Transaction Details

P.K.L Solution Private Limited held 6,00,000 equity shares prior to the transfer, representing 2.70% of the total share capital and 2.05% of the diluted share capital. The entire holding was disposed of in this single off-market transaction.

Capital Structure Context

The total equity share capital of Vivo Bio Tech remains unchanged at 2,21,90,628 equity shares of ₹10 each, aggregating ₹22,19,06,280. The diluted share capital stands at 2,93,23,111 equity shares, based on the assumption that pending convertible equity warrants and outstanding ESOPs will be exercised.

The pending instruments include:

• 6,27,409 convertible equity warrants
• 63,22,000 outstanding ESOPs

These instruments are assumed to be converted or exercised in one or more tranches for the purpose of calculating diluted voting capital.

Vivo Bio Tech Limited has scheduled its 39th Annual General Meeting (AGM) for September 30, 2026. The meeting will be conducted via Video Conferencing or Other Audio Visual Means (VC/OVAM).

The board of directors approved this schedule during a meeting held on August 22, 2026. The session commenced at 7:16 pm and concluded at 7:31 pm.

Board Approvals and Director Re-Appointments

The board also approved the re-appointment of three whole-time directors. These appointments are subject to shareholder approval at the upcoming AGM.

Mr Kalyan Ram Mangipudi retires by rotation and has offered himself for re-appointment. He brings over 23 years of experience in accounting, finance, and administration.

Based on recommendations from the Nomination and Remuneration Committee, the board approved two additional five-year terms:

• Mr Sri Kalyan Kompella: Appointed from November 3, 2026, to November 2, 2031. He has over 25 years of experience in accounting, finance, and administration.
• Dr Sankaranarayanan Alangudi: Appointed from January 6, 2027, to January 5, 2032. He is a discovery biologist with more than 45 years of experience in pharmaceutical R&D.

Corporate Governance Disclosures

The board approved the Board Report, Corporate Governance Report, and Management Discussion and Analysis report for the financial year ended March 31, 2026. These documents include all necessary annexures as required by regulatory standards.

The disclosures were made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company cited SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/1/3762/20266 dated January 30, 2026, in its filing.

No relationships between the directors were disclosed in the filing.